What is Rheumatic disorders?
Rheumatic disorders are associated with joints tendons, ligaments, bones, and muscles. They are also called as musculoskeletal diseases. The field that studies these types of disorders is called rheumatology. At present, there are more than 200 distinct rheumatic diseases. Among which most common are osteoarthritis, rheumatoid arthritis (RA), lupus, Sjogren's syndrome, gout, scleroderma, infectious arthritis, and juvenile idiopathic arthritis.
Global Rheumatic Disorders Drug Market Outlook
Rheumatic disorders are recognized among the oldest decease. The economic and social burden of these diseases is huge, without improper approaches to management and control of these diseases, the impact is expected to increase as the population grows. The increasing aging population and smoking population and certain occupations which lead to injury and overuse of joints are increasing the prevalence of rheumatic disorders. The Centres for Disease Control and Prevention announced data estimating that 54.4 million U.S. adults suffer from arthritis - equating to about 25% of the population. Ongoing research on new biologic therapies is anticipated to spur the growth by 2026. Lack of arthritis awareness in a rural region and alternative therapies is seen to have a negative influence on the growth of the market.
Global Rheumatic Disorders Drug Market Competitive Landscape
The "Global Rheumatic Disorders Drug Market" study report will provide a valuable insight with an emphasis on global market including some of the major players such as AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer, Roche, Eli Lilly, ChemoCentryx and Corbus Pharmaceuticals. Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis.
Customization of the Report
• In case of any queries or customization requirements please connect with our sales team, who will ensure that your requirements are met.
1. INTRODUCTION OF GLOBAL RHEUMATIC DISORDERS DRUG MARKET
1.1. Overview of the Market
1.2. Scope of Report
1.3. Assumptions
2. EXECUTIVE SUMMARY
3. RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH
3.1. Data Mining
3.2. Validation
3.3. Primary Interviews
3.4. List of Data Sources
4. GLOBAL RHEUMATIC DISORDERS DRUG MARKET OUTLOOK
4.1. Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Porters Five Force Model
4.4. Value Chain Analysis
5. GLOBAL RHEUMATIC DISORDERS DRUG MARKET, BY MEDICATION
5.1. Overview
5.2. Nonsteroidal anti-inflammatory medications.
5.3. Disease-modifying antirheumatic medications (DMARDs)
5.4. Corticosteroids
5.5. Biologics
5.6. Other
6. GLOBAL RHEUMATIC DISORDERS DRUG MARKET, BY APPLICATION
6.1. Overview
6.2. Rheumatoid Arthritis
6.3. Osteoarthritis
6.4. Osteoporosis
6.5. Systemic Lupus Erythematosus
6.6. Psoriatic Arthritis
6.7. Others
7. GLOBAL RHEUMATIC DISORDERS DRUG MARKET, BY GEOGRAPHY
7.1. Overview
7.2. North America
7.2.1. U.S.
7.2.2. Canada
7.2.3. Mexico
7.3. Europe
7.3.1. Germany
7.3.2. U.K.
7.3.3. France
7.3.4. Rest of Europe
7.4. Asia Pacific
7.4.1. China
7.4.2. Japan
7.4.3. India
7.4.4. Rest of Asia Pacific
7.5. Rest of the World
8. GLOBAL RHEUMATIC DISORDERS DRUG MARKET COMPETITIVE LANDSCAPE
8.1. Overview
8.2. Company Market Ranking
8.3. Key Development Strategies
9. COMPANY PROFILES
9.1. AbbVie
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments
9.2. Amgen
9.2.1. Overview
9.2.2. Financial Performance
9.2.3. Product Outlook
9.2.4. Key Developments
9.3. Johnson & Johnson
9.3.1. Overview
9.3.2. Financial Performance
9.3.3. Product Outlook
9.3.4. Key Developments
9.4. Novartis
9.4.1. Overview
9.4.2. Financial Performance
9.4.3. Product Outlook
9.4.4. Key Developments
9.5. Pfizer
9.5.1. Overview
9.5.2. Financial Performance
9.5.3. Product Outlook
9.5.4. Key Developments
9.6. Roche
9.6.1. Overview
9.6.2. Financial Performance
9.6.3. Product Outlook
9.6.4. Key Developments
9.7. Eli Lilly
9.7.1. Overview
9.7.2. Financial Performance
9.7.3. Product Outlook
9.7.4. Key Developments
9.8. ChemoCentryx
9.8.1. Overview
9.8.2. Financial Performance
9.8.3. Product Outlook
9.8.4. Key Developments
9.9. Corbus Pharmaceuticals
9.9.1. Overview
9.9.2. Financial Performance
9.9.3. Product Outlook
9.9.4. Key Developments
9.10. Selecta Biosciences
9.10.1. Overview
9.10.2. Financial Performance
9.10.3. Product Outlook
9.10.4. Key Developments
10. Appendix
10.1. Related Reports
| Price : US$ 3500 | Date : Dec 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 129 |
| Price : US$ 3500 | Date : Nov 2024 |
| Category : Medical Devices | Pages : 121 |
| Price : US$ 3500 | Date : Nov 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 130 |
| Price : US$ 3500 | Date : Nov 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 119 |
| Price : US$ 3500 | Date : Nov 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 121 |
We will be happy to help you find what you need. Please call us or write to us:
Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).
This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection
Request Sample 
Request Discount 
Inquire Before Buy
